Abstract
Activation of endogenous complement is inhibited both in the soluble phase and at the membrane surface by a group of structurally similar proteins. A possible solution to hyperacute rejection is to produce donor animals transgenic for human complement regulators. Mouse cells expressing the human complement regulatory proteins decay accelerating factor (DAF) or membrane cofactor protein (MCP) were produced both by hybridoma technology and by transfection with the appropriate cDNAs. The expression of either or both of these products protected the mouse cell from lysis by human (though not rabbit) complement in the presence of naturally occurring human anti-mouse antibody. This effect could be abrogated by the addition of monoclonal antibody against DAF or MCP. Hyperacute rejection of discordant organ xenografts is mediated by human complement. A 6.5 kilobase minigene for DAF has been microinjected into porcine fertilised ova. Forty-five pigs transgenic for human DAF have been produced. Of these, 65% transcribe message. The amount of message produced varied substantially from animal to animal and was independent of copy number integrated. Expression of human DAF on the porcine lymphocyte surface could be detected and this was able to downregulate human complement activation. Amounts of protein expressed on different tissues varied both from pig to pig and within animals from tissue to tissue. The pigs grow and develop normally with no evidence of ill effects due to possession of the transgene.
Similar content being viewed by others
Article PDF
References
Paul LC . Mechanism of humoral xenograft rejection. In: Cooper DKC, Kemp E, Reemstma K, White DJG, editors. Xenografting: the transplantation of organs and tissues between species. Berlin: Springer-Verlag, 1991:47–79.
Perper RJ, Najarian JS . Experimental renal heterotransplantation in widely divergent species. Transplantation 1966;4:377–81.
Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH . Transplantation of discordant xenografts: a review of progress. Immunol Today 1990;11:450–6.
Forty J, Watson CJ, Carey N, White DJG, Wallwork J . Perfusion of rabbit hearts with human blood results in immediate graft thrombosis which is temporally distinct from hyperacute rejection. Transplant Proc (in press).
Forty J, Carey N, White DJG, Wallwork J . Hyperacute rejection of rabbit hearts by human blood is mediated by the alternative pathway of complement. Transplant Proc (in press).
Johnston PS, Lim SML, Wang MW, Wright L, White DJG . Hyperacute rejection of xenografts in the complete absence of antibody. Transplant Proc 1991;23:877–9.
Miyagawa S, Hirose H, Shirakura R, Naka Y, Nakata S, Kawashima Y, et al. The mechanism of discordant xenograft rejection. Transplantation 1988;46:825–30.
Schilling A, Land W, Pratschke E, Brendel W . Dominant role of complement in the hyperacute xenograft rejection reaction. Surg Gynecol Obstet 1976;142:29–35.
Rey-Campos J, Rubinstein P, Rodriguez-de-Cordoba S . A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP. J Exp Med 1988;167:664–9.
Nose M, Katoh M, Okada N, Kyogoku M, Okada H . Tissue distribution of HRF 20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 1990;70:145–9.
Kearney JF, Radbruch A, Liesegang B, Rajewesky K . A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody secreting hybrid cell lines. Immunology 1979;123:1548–50.
Wu S, Seino S, Bell GI . Human anti-thrombin II (AT3) gene length polymorphism revealed by the polymerase chain reaction. Nucleic Acids Res 1989;17:6433–7.
Wright LJ, Feinstein A, Heap RB, Saunders JC, Bennett RC, Wang MW . Progesterone monoclonal antibody blocks pregnancy in mice. Nature 1982;295:415–7.
Davies HffS, Taylor JE, White DJG, Binns RM . Major transplantation antigens of pig kidney and liver: comparison between whole organs and their parenchymal constituents. Transplantation 1978;25:290–5.
Fuhlbrigge RC, Fine SM, Unanue ER, Chaplin DD . Expression of membrane interleukin 1 by fibroblasts transfected with murine interleukin 1 cDNA. Proc Natl Acad Sci USA 1988;85:5649–53.
Caras IW, Davitz MA, Rhee L, Weddell G, Martin DWJ, Nussenzweig V . Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 1987;325:545–9.
Lublin DM, Liszewski MK, Post TW, Arce MA, LeBeau MM, Rebentisch MB, et al. Molecular cloning and chromosomal localisation of human membrane cofactor protein (MCP): evidence for inclusion in the multigene family of complement-regulatory proteins. J Exp Med 1988;168:181–94.
Sparrow RL, McKenzie IFC . Hu Ly-m5: a unique antigen physically associated with HLA molecules. Hum Immunol 1983;7:1–15.
Cho S-W, Oglesby TJ, Hsi BL, Adams EM, Atkinson JP . Characterisation of three monoclonal antibodies to membrane cofactor protein (MCP) of the complement system and quantification of MCP by radioassay. Clin Exp Immunol 1991;83:257–61.
Fujita T, Kamato T, Tamura N . Characterisation of functional properties of C4 binding protein by monoclonal antibodies. J Immunol 1985;134:3320–4.
Rodriguez de Cordoba S, Dykman TR, Ginsberg-Fellner F, Ercilla G, Aqua M, Atkinson JP, Rubenstein P . Evidence for linkage between loci coding for the binding protein for the fourth component of complement (C4Bp) and for the C3b/C4b receptor. Proc Natl Acad Sci USA 1984;81:7890–2.
Weiss JH, Morton CC, Bruns GAP, Weis JJ, Klickstein LB, Wong WW, Fearon DT . not known. J Immunol 1987;138:312–5.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
White, D., Cozzi, E., Langford, G. et al. The control of hyperacute rejection by genetic engineering of the donor species. Eye 9, 185–189 (1995). https://doi.org/10.1038/eye.1995.37
Issue Date:
DOI: https://doi.org/10.1038/eye.1995.37
Keywords
This article is cited by
-
The immunobiology and clinical use of genetically engineered porcine hearts for cardiac xenotransplantation
Nature Cardiovascular Research (2022)